- US-listed companies
- ALNYLAM PHARMACEUTICALS, INC.
- Income statement
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Income statement
Market cap
$40.5B
P/E ratio
131.1x
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 100 | - | - | - | - | - | - | - | 75 | 220 | 493 | 844 | 1,037 | 1,828 | 2,248 | 3,714 |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | |||||||
| Cost of revenue | - | - | - | - | - | - | - | - | 2 | 25 | 78 | 115 | 140 | 268 | 307 | 677 |
| Research & development | 106 | 99 | 87 | 113 | 190 | 276 | 382 | 391 | 505 | 655 | 655 | 792 | 883 | 1,004 | 1,126 | 1,320 |
| Selling, general & administrative | - | - | - | - | - | - | - | - | 382 | 479 | 588 | 621 | 771 | 796 | 976 | 1,211 |
| Operating margin (%) | - | - | - | - | - | - | - | |||||||||
| Operating expenses | 144 | 138 | 196 | 140 | 456 | 337 | 472 | 590 | 890 | 1,159 | 1,321 | 1,553 | 1,822 | 2,110 | 2,425 | 3,212 |
| Operating income | -44 | -55 | -129 | -93 | -405 | -296 | -425 | -500 | -815 | -939 | -828 | -709 | -785 | -282 | -177 | 502 |
| Income before tax | -43 | -58 | -117 | -92 | -401 | -290 | -410 | - | -761 | -885 | -856 | -852 | -1,127 | -434 | -377 | 323 |
| Pretax margin (%) | -43 | - | - | - | - | - | - | - | -1,015.5 | -402.8 | -173.6 | -100.9 | -108.6 | -23.7 | -16.8 | 8.7 |
| Provision for income taxes | 1 | - | -11 | -3 | - | - | - | - | 1 | 1 | 3 | 1 | 4 | 7 | -99 | 9 |
| Effective tax rate (%) | - | - | - | - | - | |||||||||||
| Net income | -44 | -58 | -106 | -89 | -360 | -290 | -410 | -491 | -761 | -886 | -858 | -853 | -1,131 | -440 | -278 | 314 |
| Net income margin (%) | - | - | - | - | - | - | - | |||||||||
| Earnings per share | - | - | - | - | - | - | - | - | - | - | - | -7.2 | -9.3 | -3.52 | -2.18 | 2.39 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -7.2 | -9.3 | -3.52 | -2.18 | 2.33 |
| EBITDA | ||||||||||||||||
| EBITDA margin (%) | - | - | - | - | - | - | - |